Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION AD-JP: Real-world long-term outcomes with lecanemab in early Alzheimer's disease in Japan
jRCT2031260237Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of lecanemab in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd. Primary endpoint: Time to progression to next AD stage (CDR global score). Started Jun 2026; status: recruiting.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031260237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260237.